Background: Recombinant factor VIIa (rFVIIa) is a highly purified recombinant protein. It is approved for the treatment and prevention of bleeding episodes associated with congenital factor VII deficiency, congenital hemophilia with inhibitors, and Glanzmann's thrombasthenia. The most commonly reported adverse events are thrombolytic in nature. In this report, we present a successful desensitization protocol administered to an infant with a history of anaphylaxis to rFVIIa.

中文翻译：

---

继发于重组因子 VIIa 的过敏反应后婴儿的成功脱敏方案

背景：重组因子 VIIa (rFVIIa) 是一种高度纯化的重组蛋白。它被批准用于治疗和预防与先天性因子 VII 缺乏症、具有抑制剂的先天性血友病和 Glanzmann 血小板无力症相关的出血事件。最常报告的不良事件本质上是溶栓性的。在本报告中，我们介绍了对有 rFVIIa 过敏史的婴儿进行的成功脱敏方案。